Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sudhakar M. Pai
Observed names:
S. Pai,
Sudhakar M Pai,
Sudhakar Pai
Institution:
Akros Pharma Inc. (United States)
Observed institutions:
Merck & Co., Inc., Rahway, NJ, USA (United States),
Bristol-Myers Squibb (United States),
American College of Clinical Pharmacy,
Janssen (United States),
Akros Pharma Inc. (United States),
University of Missouri–Kansas City
show all 6
ORCID:
0000-0001-8091-546X
Observed ORCID:
0000-0001-8091-546X
OpenAlex ID:
A5063284241
Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults
2003
·
Rachel Courtney
, Sudhakar Pai
, et al.
·
Antimicrobial Agents and Chemotherapy
·
300
Bioavailability and Metabolism of Mometasone Furoate following Administration by Metered‐Dose and Dry‐Powder Inhalers in Healthy Human Volunteers
2000
·
Melton B. Affrime
, Francis Cuss
, et al.
·
The Journal of Clinical Pharmacology
·
95
Characterization of AUCs from Sparsely Sampled Populations in Toxicology Studies
1996
·
Sudhakar M. Pai
, Scott H. Fettner
, et al.
·
Pharmaceutical Research
·
30
Effect of Felbamate on the Pharmacokinetics of Lamotrigine
1996
·
Robert Colucci
, Paul Glue
, et al.
·
The Journal of Clinical Pharmacology
·
29
Single‐dose pharmacokinetics of felbamate in patients with renal dysfunction
1997
·
P. Glue
, W. Sulowicz
, et al.
·
British Journal of Clinical Pharmacology
·
28
PDF
An improved LC–ESI–MS–MS method for simultaneous quantitation of rosiglitazone and N-desmethyl rosiglitazone in human plasma
2008
·
Grace O’Maille
, Sudhakar M. Pai
, et al.
·
Journal of Pharmaceutical and Biomedical Analysis
·
26
Population Pharmacokinetic Analysis of Didanosine (2′,3′‐Dideoxyinosine) Plasma Concentrations Obtained in Phase I Clinical Trials in Patients with AIDS or AIDS‐Related Complex
1992
·
Sudhakar M. Pai
, Umesh A. Shukla
, et al.
·
The Journal of Clinical Pharmacology
·
24
Elevation of Serum Aluminum in Humans on a Two‐Day Sucralfate Regimen
1987
·
Sudhakar Pai
, Srikumaran Melethil
, et al.
·
The Journal of Clinical Pharmacology
·
23
Kinetics of Aluminum in Rats I: Dose-Dependent Elimination from Blood after Intravenous Administration
1989
·
Sudhakar M. Pai
, Srikumaran Melethil
·
Journal of Pharmaceutical Sciences
·
18
A Mass Balance Study of 14C‐Labeled JTZ‐951 (Enarodustat), a Novel Orally Available Erythropoiesis‐Stimulating Agent, in Patients With End‐Stage Renal Disease on Hemodialysis
2019
·
Sudhakar M. Pai
, Jeffrey Connaire
, et al.
·
Clinical Pharmacology in Drug Development
·
17
Pharmacodynamic parameter estimation: Population size versus number of samples
2005
·
Suzette Girgis
, Sudhakar M. Pai
, et al.
·
The AAPS Journal
·
17
Off‐Label Use of Ketamine: A Challenging Drug Treatment Delivery Model With an Inherently Unfavorable Risk‐Benefit Profile
2021
·
Sudhakar M. Pai
, Jean‐Michel Gries
·
The Journal of Clinical Pharmacology
·
16
A semimechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans
2013
·
Antonio Cabal
, Khamir Mehta
, et al.
·
Journal of Bone and Mineral Research
·
13
PDF
Science and Evidence‐Based Review and Approval of COVID‐19 Vaccines: A Statement of Support for the US FDA
2020
·
Sudhakar M. Pai
, Ahmed A. Othman
, et al.
·
The Journal of Clinical Pharmacology
·
10
PDF
A sensitive LC-MS-MS assay for the determination of lapatinib in human plasma in subjects with end-stage renal disease receiving hemodialysis
2018
·
Geralyn P. Kocan
, Mike (Qingtao) Huang
, et al.
·
Journal of Chromatography B
·
10
Discovery and SAR of JTE-151: A Novel RORγ Inhibitor for Clinical Development
2024
·
Takaki Maeba
, Kazuyuki Hirata
, et al.
·
Journal of Medicinal Chemistry
·
9
A highly sensitive and selective UPLC-MS/MS assay for the determination of enarodustat (JTZ-951) in human plasma
2021
·
Sudhakar Pai
, Mike Qingtao Huang
, et al.
·
Journal of Chromatography B
·
7
Hemodialysis Clearance of Enarodustat (JTZ‐951), an Oral Erythropoiesis Stimulating Agent, in Patients with End‐Stage Renal Disease
2021
·
Sudhakar M. Pai
, Hiroyuki Yamada
·
Clinical Pharmacology in Drug Development
·
7
Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End‐Stage Renal Disease on Maintenance Hemodialysis
2019
·
Sudhakar M. Pai
, Philip Chaikin
, et al.
·
The Journal of Clinical Pharmacology
·
7
Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension
1995
·
ScottH. Fettner
, S. Pai
, et al.
·
European Journal of Clinical Pharmacology
·
7
Pharmacokinetics of Enarodustat in Non‐Japanese and Japanese Healthy Subjects and in Patients With End‐Stage Renal Disease on Hemodialysis
2023
·
Sudhakar M. Pai
, Siva Rama Prasad Kambhampati
, et al.
·
Clinical Pharmacology in Drug Development
·
6
Population Pharmacodynamic Parameter Estimation from Sparse Sampling: Effect of Sigmoidicity on Parameter Estimates
2009
·
Sudhakar M. Pai
, Suzette Girgis
, et al.
·
The AAPS Journal
·
6
PDF
Performance of Bailer's Method for AUC Confidence Intervals from Sparse Non-Normally Distributed Drug Concentrations in Toxicokinetic Studies
1996
·
Sudhakar M. Pai
, Jerry R. Nedelman
, et al.
·
Pharmaceutical Research
·
6
Evaluation of Drug–Drug Interaction Potential of Enarodustat (JTZ‐951) Using a Cytochrome P450 Probe Cocktail
2023
·
Sudhakar M. Pai
, Hiroyuki Yamada
, et al.
·
Clinical Pharmacology in Drug Development
·
4
PDF
Thorough QT/QTc Evaluation of the Cardiac Safety of Enarodustat (JTZ‐951), an Oral Erythropoiesis‐Stimulating Agent, in Healthy Adults
2021
·
Sudhakar M. Pai
, Hiroyuki Yamada
, et al.
·
Clinical Pharmacology in Drug Development
·
4
Show more works
View as search
Works count:
35
Citation count:
733
H-index:
13
I10-index:
15
Year
Topic
Type
